uniQure N.V. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
35,606.70
49,131.50
79,265.70
73,374.00
79,260.00
83,304
Depreciation, Depletion & Amortization
710.30
2,041.40
4,925.80
6,089.00
7,543.00
6,500
Other Funds
-
-
-
-
582.00
6,737
Funds from Operations
28,124.30
34,868.30
50,021.20
61,897.00
49,597.00
69,836
Changes in Working Capital
22,655.80
1,339.70
69,166.70
10,292.00
14,673.00
6,201
Net Operating Cash Flow
5,468.50
33,528.60
19,145.50
72,189.00
64,270.00
76,037
Capital Expenditures
7,949.80
25,382.90
9,548.90
17,172.00
5,583.00
Purchase/Sale of Investments
-
-
-
613.00
-
Net Investing Cash Flow
7,949.80
27,323.40
9,548.90
17,785.00
5,583.00
Issuance/Reduction of Debt, Net
25,686.80
9,322.30
865.00
148.00
1,322.00
Net Financing Cash Flow
44,663.70
92,130.90
152,545.40
2,445.00
90,074.00
Net Change in Cash
31,261.40
39,009.40
166,685.20
89,130.00
27,527.00
Free Cash Flow
7,242.20
54,445.30
12,856.80
87,477.00
68,731.00
Deferred Taxes & Investment Tax Credit
-
-
531.20
1,094.00
209.00
231
Net Assets from Acquisitions
-
1,940.60
-
-
-
Change in Capital Stock
18,977.00
82,808.60
153,410.30
2,593.00
89,334.00
Exchange Rate Effect
15.90
7,730.50
4,543.20
1,601.00
7,306.00

About uniQure

View Profile
Address
Paasheuvelweg 25a
Amsterdam Noord-Holland 1105 BP
Netherlands
Employees -
Website http://www.uniqure.com
Updated 07/08/2019
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, the Netherlands.